Prion: the infectious protein in neurodegenerative diseases

M.M. Vita Kurniati, Septelia Inawati Wanandi

Abstract

Prion particle is an infectious agent causing neurodegenerative diseases in humans and animals, such as Creutzfeldt-Jakob disease, kuru, Gerstmann-Sträussler-Scheinker syndrome, and familial fatal insomnia in humans; mad cow disease, scrapie, and feline spongiform encephalopathy in animals. This particle is devoid of nucleic acid and seems to be composed of protein. The normal prion protein (PrP\(^\text{C}\)) is converted into its abnormal isoform (PrP\(^\text{Sc}\)) posttranslationally. The conversion of PrP\(^\text{C}\) into PrP\(^\text{Sc}\) involves a conformational change whereby the \(\alpha\)-helical content decreases and the amount of \(\beta\)-sheet increases. The formation of PrP\(^\text{Sc}\) requires an unknown protein X which might function as a molecular chaperone. Many prion characteristics have been revealed in these last two decades, such as physical, chemical, strain, molecular biology, and immunological characteristics. Some investigators revealed the topological forms of prion protein in the endoplasmic reticulum membrane and their role in the pathophysiological process of the disease. But still prion diseases continue to raise many unanswerable questions to be investigated. One of the unanswerable questions is prion multiplication. Many prion multiplication models are suggested by investigators; one constant finding is that prion replication requires the interaction of PrP\(^\text{C}\)-PrP\(^\text{Sc}\). The studies of pathogenesis of prion diseases need much more attention to develop an effective therapy for these neurodegenerative diseases. Diagnosis of prion diseases is based on the clinical and histopathological findings, and immunochromatography tests of some proteins in cerebrospinal fluid. Immunochromatography tests of proteins in cerebrospinal fluid are important in developing pre-mortem diagnosis of prion diseases.

Keywords: scrapie, kuru, Creutzfeldt-Jakob disease, conformational change

During the past two decades, a transmissible pathogen causing a group of human and animal neurodegenerative diseases has been found. This infectious agent is different from both viroids and viruses. Some investigators had indicated that this agent could not be inactivated by procedures modifying or hydrolyzing nucleic acid, such as nuclease digestion, or UV irradiation.\(^1\)\(^,\)\(^2\) Other evidence shows that the agent contains a protein that is required for infectivity, and its infectivity is lost upon inactivation by protease K, detergent (sodium dodecyl sulphate), guanidinium thiocyanate, or urea (Table 1).\(^2\) On the basis of these evidence, the term "prion" was introduced to distinguish this infectious pathogen from those responsible for viral illness, i.e. viruses and viroids.\(^1\) Prion has an operational definition, i.e. small proteinaceous infec-
tious particles which resist inactivation by procedures that modify nucleic acids. The term prion emphasizes that the infectivity of this transmissible pathogen of the neurodegenerative diseases depends on a protein component.1,2

Prion diseases are neurodegenerative disorders of humans and animals causing severe neurologic dysfunction and death. Prions cause four transmissible neurodegenerative diseases of humans and six of animals. Human prion diseases, can manifest as infectious, sporadic, and inherited forms, include kuru, Creutzfeldt-Jakob disease (CJD), fatal familial insomnia (FFI), and Gerstmann-Sträussler-Scheinker syndrome (GSS). The animal prion diseases include the following: scrapie of sheep, transmissible mink encephalopathy (TME), chronic wasting disease (CWD) of mule, deer and elk, bovine spongiform encephalopathy (BSE), feline spongiform encephalopathy (FSE), and exotic ungulate encephalopathy.1

Table 1. Stabilities of prion and viroids against physical, chemical and enzymatic treatment (modified from Prusiner2)

| Treatment                  | Viroid | Prion |
|----------------------------|--------|-------|
| Physical treatment:        |        |       |
| UV irradiation 254 nm      | +      | -     |
| Chemical treatment:        |        |       |
| SDS                        | -      | +     |
| Phenol                     | -      | +     |
| Urea 3 M                   | -      | +     |
| Guanidium thiocyanate 1 M  | -      | +     |
| Psoralen                   | -      | -     |
| Enzymatic treatment:       |        |       |
| RNase A                    | +      | -     |
| DNase                      | +      | -     |
| Proteinase K               | -      | +     |
| Trypsin                    | -      | +     |

+ = inactivated; - = no change in infectivity

The normal cellular prion protein (PrPC) has an abnormal isoform, called scrapie prion protein (PrPSC). The conversion of PrPC into PrPSC is a posttranslationally modified process that involves a change in the conformation without evidence for chemical modification. Both PrP isoforms are encoded by a chromosomal gene. The human PrP gene maps to the short arm of chromosome 20 and is designated PRNP; the mouse PrP gene maps to chromosome 2 and is designated Prn-p.1

Characteristic of the cellular prion protein and scrapie prion protein

The PrPSC and PrPSC have a molecular weight (Mr) of 33 to 35 kD.1 Both PrPSC and PrPSC are encoded by a single exon of the chromosomal gene as proteins with the same 254 amino acid sequence. The first 22-residues at the NH2 terminal is cleaved posttranslationally.3,4 The PrP protein is glycosylated with N-linked oligosaccharides.4 The PrPSC is a plasma membrane glycoprotein. PrPSC is anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety located at the COOH terminus of the polypeptide chain. The anchor is added post-translationally in the endoplasmic reticulum, following cleavage of a 23-residue COOH-terminal hydrophobic sequence which serves as a signal for the anchor attachment.3

The two PrP isoforms can be distinguished by their different properties. In the proteinase K digestion, PrPSC is completely hydrolyzed, whereas only the first 67 amino acids at the NH2 terminal of PrPSC are hydrolyzed and converted PrP 33-35Sc to PrP 27-30 (PrP with a Mr of 27 to 30 kD). PrP 27-30 is also called the protease-resistant fragment of PrPSC. After detergent solubilization, PrPSC can be solubilized, whilst PrPSC is insoluble, but does not form an ordered array and PrP 27-30 polymerizes into amyloid rods.3,4 The presence of PrP amyloid rods in some prion diseases has led to assumptions that amyloid formation is essential for the formation of PrPSC. However, PrPSC can be formed in the absence of amyloid, and the presence of amyloid plaques is not obligatory for prion diseases.3

The physiological function of PrPSC is unknown, but it appears to be unnecessary since mice in which the PrP gene has been deleted develop normally and are healthy for more than 9 months.1 Recently, some investigators suggested several roles of PrP, such as: postsynaptic PrP might be necessary for GABA-dependent synapses to be fully functional, PrP lacking animals exhibit altered sleep patterns and rhythms of circadian activity. PrP also contributes to the prion diseases; the PrP fragment, PrP 106-126, is toxic to cortical and cerebellar cells.5

The studies of PrP indicate that there are two distinct strains of transmissible mink encephalopathy prions, designated hyper (HY) and drowsy (DY). These strains can be distinguished by different physicochemical properties of the PrPSC. DY PrPSC seems to be more protease-sensitive than HY PrPSC.
Studies of CJD demonstrate four distinct patterns of protease-resistant PrP on Western blots after limited proteolysis. Types 1 and 2 are seen in sporadic CJD and also in some iatrogenic CJD. The third type is seen in acquired prion diseases that arise from a peripheral route of exposure to prions, while central nervous system (CNS) exposure typically resembles sporadic CJD. Type 4 is associated with a new variant CJD which arises from dietary exposure to bovine prions. The bands pattern of type 4 is similar to type 3, but it can be distinguished from all three types of CJD by a characteristic pattern of band intensities. Type 1 is always associated with genotype MM, type 2 with all genotypes (MM, MV or VV). Type 3 is seen in genotype MV or VV, and type 4 in genotype MM.6

The transmission of prions from one species to another is generally accompanied by a prolonged incubation time relative to transmission to which the host species is the same.4,7 This is often referred to as the "species barrier". The species barrier concept is important in assessing the risk for humans of developing CJD after consumption of scrapie-infected lamb or BSE beef. There are three factors that might contribute to the species barrier: (i) the difference in amino acid sequence of PrP between prion donor and recipient, (ii) strain of prion, (iii) the species specificity of protein X, a factor that binds to PrP<sup>C</sup> and facilitates PrP<sup>Sc</sup> formation.7 PrP<sup>C</sup> is most efficiently converted to PrP<sup>Sc</sup> when the amino acids sequences of PrP<sup>C</sup> and PrP<sup>Sc</sup> are identical.8

Studies of PrP genes responsible for the prolonged incubation time in mice have demonstrated genetic linkage between Prn-p gene and a gene modulating incubation time, Prn-i. This Prn-i gene maps to mouse chromosome 2.1,4 Prn-p and Prn-i are very closely linked and lie adjacent on the chromosome.4 The incubation time is also influenced by the PrP sequence. When prions are passaged into mice with a nonmatching PrP sequence, the incubation time is longer than that in mice with a matching PrP sequence.8

Another characteristics of this agent are that the agent is not destroyed by boiling in water, and it is not inactivated by standard exposure to an autoclave to wet heat at 121 °C for 15 min. Exposure to 134-138 °C for 18 min in porous-load autoclave is currently recommended but may not be adequate in all circumstances. The scrapie agent withstands alcohol and strong disinfectants such as formaldehyde and glutaraldehyde. Formaldehyde may even increase its heat-stability. It may be inactivated by exposure for 1 hour to sodium hypochlorite providing 2% available chlorine. The infectivity of scrapie affected brain homogenate can pass through small-pore filters.9

The formation of the scrapie prion protein

The prion diseases are due to the conversion of PrP<sup>C</sup> into PrP<sup>Sc</sup>. PrP<sup>Sc</sup> formation is a posttranslational process involving only a conformational change in PrP<sup>C</sup>.7 In scrapie infected cells, PrP<sup>C</sup> molecules exit to the cell surface then interact with exogenous PrP<sup>Sc</sup>. PrP<sup>C</sup>-PrP<sup>Sc</sup> re-enter into the cell through a subcellular compartment bounded by cholesterol-rich membranes which might be caveola or endosome.10 The formation of new PrP<sup>Sc</sup> occurs between the cell surface and internalization in an endosome, non-acidic compartment. Then PrP<sup>C</sup> and PrP<sup>Sc</sup> are transported to lysosomes. Following transport to lysosomes, PrP<sup>C</sup> is degraded, while PrP<sup>Sc</sup> may be shunted back to the cell surface or induce vacuolar pathology.11 A critical level of accumulated PrP<sup>Sc</sup> in the lysosomes will disrupt lysosomal membranes, releasing hydrolases into the cell. These enzymes will cause cytoskeletal disruption and spongiform changes.12

Conformational studies of prion proteins showed that PrP<sup>C</sup> has a secondary structure which contains about 43% β-helix and only 3% β-sheet.10,13 Molecular modeling studies predicted four putative α-helical regions of PrP<sup>C</sup>, denoted helix 1 through helix 4 (H1 through H4).7,10,13 Within the four helical regions, 15 residues were identified as potential sites that would mediate helix-helix interaction.13 It is suggested that H1 and H2 are converted into β-sheet structures during the formation of PrP<sup>Sc</sup>, while H3 and H4 remain unchanged (Fig. 1A and 1B).10

Presumably, there is a central domain of PrP<sup>C</sup> (approximately residues 95 to 170) that binds to PrP<sup>Sc</sup> during the formation of nascent PrP<sup>Sc</sup>. This domain shows higher homology between cattle and humans than between sheep and humans, which raises the possibility that prion transmission from cattle to humans may occur more readily than from sheep to humans. The NH2-terminal domain of PrP<sup>C</sup> is thought to form the interface where PrP<sup>Sc</sup> binds.7

In contrast to PrP<sup>C</sup>, the β-sheet content of PrP<sup>Sc</sup> is 43% and α-helix content is 30%. Furthermore, PrP 27-30 contains 54% β-sheet. The formation of PrP<sup>Sc</sup> involves refolding of the NH2-terminal helices (H1 and H2) into β-sheets (Fig. 1C). The major conformational change of PrP<sup>C</sup> into PrP<sup>Sc</sup> has been localized to residues 90 to 112.7
Figure 1. (A) Schematic drawing of tertiary structural model of PrP<sup>C</sup>.<sup>11</sup> (B) Plausible model for the tertiary structure of PrP<sup>C</sup>.<sup>10</sup> (C) Plausible model for the tertiary structure of PrP<sup>Ck</sup>.<sup>10</sup>
Mutations of PrP gene can destabilize the conformation of PrPSc and facilitate its refolding into PrPSc. Usually PrP gene mutations occur at or near the helix-helix interaction residues. These mutations could disrupt or destabilize the structure of PrPC and produce mice or humans which are susceptible to prion disease. Mutation at codon 178 in fatal familial insomnia and familial CJD would eliminate the negative charge that interacts with the positive end of a helix dipole and destabilizes H3. Another mutation at codon 210 that also produces familial CJD would disrupt the H4 - H1 interaction and, thus, perturbs the structure of PrPC.13

Synthesis of PrPSc probably also involves another protein which is not known. This protein X, possibly a "chaperone", facilitates the refolding process of α-helices in PrPC into β-sheets in PrPSc.7,10 The COOH-terminal domain of H3 in PrPSc appears to contain the site for protein X binding.7 The binding of PrPSc to protein X seems to exhibit the highest affinity when these two proteins are from the same species.10

Prion protein receptor

The cell-surface form of the prion protein, PrPC, is anchored to the plasma membrane by a glycosyl-phosphatidylidyinositol (GPI) moiety. The internalization of PrPC seems to require a protein, a receptor or a prion binding protein. To convert PrPC into PrPSc, internalization is needed. Martin et al.14 noted that there is a neurotoxic region in human prion (residues 106-126) that contains the binding site recognized by a putative cell receptor. Rieger et al.15 identified the 37 kD laminin receptor precursor (LRP) as interacting with PrPSc in yeast, insect and mammalian cells. The 37 kD LRP is located on the cell surface, and it may act as a receptor or co-receptor for the prion protein.15

Multiplication of prions

The mechanism by which prions multiply is not yet clearly established. Several plausible models for the multiplication of prions can be proposed. If the prion contains a small nucleic acid molecule, then this nucleic acid may stimulate the production of PrPSc. The PrPSc would stimulate the production of new copies of the hypothetical small nucleic acid, then this new nucleic acid may combine with PrPSc to form a highly stable infectious complex (Fig. 2A). Alternatively, prions may be devoid of nucleic acid, and PrPSc may stimulate its own synthesis. The PrPSc may combine with the product of PrP-1 gene, and this complex would stimulate or catalyze the synthesis of PrPSc (Fig. 2B). It also will be possible that PrPSc alone stimulates the biosynthesis of new PrPSc molecules (Fig. 2C).4

Another alternative mechanism is a process in which PrPSc (circles) binds to PrPC (squares) forming heterodimers that function as replication intermediates in the synthesis of PrPSc (Fig. 2D).1

Another plausible model for prion multiplication can be explained by a conformational model. According to this model, the structure of PrPC would generate a partially unfolded monomer (PrP8) that is an intermediate structure in the formation of PrPSc.8,10 PrPSc may revert to PrPC, be degraded, or form PrPSc. Normally, the concentration of PrPSc would be low, and PrPSc would be formed in insignificant amounts.8

In the case of infectious prion diseases, an exogenous prion containing PrPSc would act as a template to promote the conversion of PrP8 into PrPSc, which is likely to be an irreversible process.8

Prion in neurodegenerative diseases

Vol 8, No 3, July - September 1999

Prion protein receptor

The cell-surface form of the prion protein, PrPC, is anchored to the plasma membrane by a glycosyl-phosphatidylidyinositol (GPI) moiety. The internalization of PrPC seems to require a protein, a receptor or a prion binding protein. To convert PrPC into PrPSc, internalization is needed. Martin et al.14 noted that there is a neurotoxic region in human prion (residues 106-126) that contains the binding site recognized by a putative cell receptor. Rieger et al.15 identified the 37 kD laminin receptor precursor (LRP) as interacting with PrPSc in yeast, insect and mammalian cells. The 37 kD LRP is located on the cell surface, and it may act as a receptor or co-receptor for the prion protein.15

Multiplication of prions

The mechanism by which prions multiply is not yet clearly established. Several plausible models for the multiplication of prions can be proposed. If the prion contains a small nucleic acid molecule, then this nucleic acid may stimulate the production of PrPSc. The PrPSc would stimulate the production of new copies of the hypothetical small nucleic acid, then this new nucleic acid may combine with PrPSc to form a highly stable infectious complex (Fig. 2A). Alternatively, prions may be devoid of nucleic acid, and PrPSc may stimulate its own synthesis. The PrPSc may combine with the product of PrP-1 gene, and this complex would stimulate or catalyze the synthesis of PrPSc (Fig. 2B). It also will be possible that PrPSc alone stimulates the biosynthesis of new PrPSc molecules (Fig. 2C).4

Another alternative mechanism is a process in which PrPSc (circles) binds to PrPC (squares) forming heterodimers that function as replication intermediates in the synthesis of PrPSc (Fig. 2D).1

Another plausible model for prion multiplication can be explained by a conformational model. According to this model, the structure of PrPC would generate a partially unfolded monomer (PrP8) that is an intermediate structure in the formation of PrPSc.8,10 PrPSc may revert to PrPC, be degraded, or form PrPSc. Normally, the concentration of PrPSc would be low, and PrPSc would be formed in insignificant amounts.8

In the case of infectious prion diseases, an exogenous prion containing PrPSc would act as a template to promote the conversion of PrP8 into PrPSc, which is likely to be an irreversible process.8

Prion in neurodegenerative diseases

Vol 8, No 3, July - September 1999
Figure 2. Some possible mechanisms of prion multiplication
(A) A small nucleic acid triggers the synthesis of PrPSc4 Prn-p = mouse PrP gene, Prn-i = a gene modulating incubation time. (C) PrPSc by itself triggers reactions that produce more PrPSc. (D) PrPSc binds to PrPSc and forms heterodimers that function as replication intermediates.
The role of the immune system in the prion disease

It has been noted for years that scrapie infection fails to induce an immune response. This lack of immune response to the infectious scrapie particle can be explained by the discovery that the major component of scrapie (PrP\textsuperscript{Sc}) is a modified form of the host cellular protein (PrP\textsuperscript{C}); thus, organisms may not view the scrapie particle as foreign. It is also reasonable to suggest that animals are tolerant to both PrP\textsuperscript{C} and PrP\textsuperscript{Sc}, because PrP\textsuperscript{C} is expressed in most tissues of uninfected animals and is even found on the surface of T lymphocytes,\textsuperscript{16} and B cells.\textsuperscript{17} The T and B cells' tolerance to PrP would explain the absence of immune response to scrapie infection.\textsuperscript{16}

A scrapie infection from a different species or in the PrP-deficient mice also can not induce an immune response although the scrapie particle would be considered foreign. This absence of immune response is due to the failure of scrapie infection to activate the nonspecific immune mediators that normally signal the invasion of pathogenic microorganisms, such as interferons, tumor necrosis factor, interleukin 1 (IL-1), and IL-6. In the absence of these nonspecific mediators, even foreign proteins do not elicit an immune response. This situation suggests that successful approaches to treating prion diseases cannot depend on activating the immune system.\textsuperscript{16}

Topology of prion protein

Studies of PrP topology at the endoplasmic reticulum (ER) membrane have revealed two distinct forms of PrP: one that is fully translocated into the ER lumen and is termed the secretory form (secPrP); and one that spans the membrane (transmembrane) (CmPrP). Digestion of transmembrane form with proteases added to the outside of the membrane yielded two fragments: one is COOH-terminal derived and glycosylated (CmPrP), and the other is NH2-terminal derived and unglycosylated (NmPrP). These data indicated that transmembrane PrP chains span the membrane twice, with the NH2- and COOH-termini of the molecule in the ER lumen (Fig. 3).\textsuperscript{18}

Hegde et al. examined the possible role of PrP topology in neurodegeneration. Their data showed a marked increase in CmPrP production at the ER membrane of scrapie infected hamster, with a concomitant decrease in the secPrP. The amount of NmPrP remained unchanged. These findings suggest that CmPrP is involved in the development of spontaneous neurodegenerative disease.\textsuperscript{18}

In normal cells the percentage of CmPrP in vivo was consistently lower than that found in vitro. This data suggests that cells normally have mechanisms to prevent the accumulation of this potentially pathogenic protein. Mutation of PrP gene may cause overexpression of CmPrP, which exceed the cell's ability to eliminate or prevent the synthesis of CmPrP. As a result, CmPrP would accumulate, leaves the ER, and trigger the disease.\textsuperscript{18}

The pathogenesis of CmPrP-associated neurodegenerative disease includes at least three distinct steps (Fig. 4). First, nascent PrP is synthesized in the secPrP, NmPrP, or CmPrP form. Second, the CmPrP form may be rapidly degraded in the ER or, in some cases, may be able to escape degradation to a post-ER compartment. Finally, in the post-ER compartment, CmPrP is proposed to cause disease. How the CmPrP can cause the disease, is not yet known. The pathway involving the increase in CmPrP may not be the only pathway of neurodegeneration.\textsuperscript{18}
Fatal familial insomnia

Fatal familial insomnia (FFI) exhibits insomnia, dysautonomia, ataxia, dysarthria, dysphagia, myoclonus, and signs of pyramidal tract dysfunction. This FFI is caused by a mutation at codon 178 (Asp→Asn). However, in contrast to the inherited CJD with a valine residue at codon 129, a methionine residue was always found at codon 129 of FFI patients.20

Bovine spongiform encephalopathy (mad cow disease)

Bovine spongiform encephalopathy (BSE) was first recognized in Britain in November 1986 in cattle. The cows initially became apprehensive, hyperesthetic, and uncoordinated. Then they became hard to handle, and in some cases they progressed to frenzy, which led to the name "mad cow disease".20 The mean incubation period is four to five years.7,20

The BSE agent can be transmitted to another species, such as calves, sheep, goats, and mice, by the oral route, in some cases by very high-challenge doses only. Transmission orally to sheep and goats was possible using 0.5 g infected bovine brain; and 1 g of brain was effective in cows.9 In humans, there are three possible routes of infection. First, by implantation or injection of bovine-derived materials or preparations associated with bovine products, including "catgut" sutures. Second, workers in animal feed preparation might have been at risk of inhaling infected dust or acquiring the agent conjunctivally. Infection by ingestion is the third possible route. High-titre infectivity challenges seem to be associated with bovine brain, retina, and spinal cord. Medium infectivity is associated with lymphoreticular tissues. Other tissues, including skeletal muscle (meat), milk, and blood, had no detectable infectivity.21

The bovine prions in humans can cause some cases which differ in several ways from other cases of CJD. These cases are being called variant Creutzfeld-Jakob disease (vCJD) or new variant Creutzfeld-Jakob disease (nvCJD). The patients are young (the age range is between 16 and 41), and presenting behavioral changes, ataxia, and peripheral sensory disturbances, while progressive dementia developed later. The PrP genes in all cases analyzed showed no mutation and are homozygous for methionine at codon 129 (the same as in cattle).20

Alzheimer's disease

The hallmark of Alzheimer's disease is the accumulation of several abnormal proteins in the brain, such as amyloid β protein, β protein precursor, Apo E, and PrP. These proteins are present in the muscle fibers. The muscle fibers also demonstrated increased PrPSc mRNA while the abnormal brains of patients with prion diseases did not have increased PrPSc mRNA.22

Diagnosis of prion diseases

The diagnosis of prion diseases is based on clinical and neuropathological findings. The typical neuropathological findings of these diseases are spongiform change, astrocytosis, and neuronal loss. Of these the most specific is the spongiform change, which consists of diffuse or focally clustered, small, round vacuoles that may become confluent. In some cases, there are amyloid plaques composed of extracellular accumulation of PrP.23 The definitive diagnosis can only be made by histopathological examination of brain biopsy specimen.23,24 Brain biopsy, however, places patients and health personnel at risk and may miss the site of disease.23

Most cerebrospinal fluid proteins in CJD patients showed two 30-kD proteins detected by two-dimensional electrophoresis and designated as protein 130 and 131. These two proteins are 14-3-3 proteins. The 14-3-3 protein was abundant in an extract of normal human brain, but it was not found in normal serum and in serum from CJD patients. In humans and other mammals, 14-3-3 is a normal neuronal protein consisting of several isoforms, and it plays a part in conformational stabilization of other proteins. The presence of 14-3-3 in cerebrospinal fluid may be due to massive neuronal disruption and the leakage of brain proteins into cerebrospinal fluid. The quantity of 14-3-3 present in cerebrospinal fluid may be proportional to the rate and the amount of neuronal destruction.23

The 14-3-3 proteins can be detected by an immunoassay method. This 14-3-3 protein can also be found in cerebrospinal fluid from patients with herpes simplex encephalitis or recent infarctions. Therefore, it should be emphasized that the need to use the 14-3-3 marker as a test is only useful in an appropriate clinical setting. For a patient with dementia, the detection of 14-3-3 in cerebrospinal fluid strongly supports a diagnosis of CJD.23

Some other studies in small numbers of patients have suggested that there is another protein in cerebrospinal fluid which is increased in the early phase and returns to normal in the late stages of the CJD. This protein is
neuron-specific enolase (NSE). This enzyme is a 78-kD protein, localized in neurons and neuroendocrine cells, synthesized virtually completely within the central nervous system. Raised NSE levels in cerebrospinal fluid have also been reported in other neurological disorders, such as brain trauma, brain tumors, subarachnoid haemorrhage, and acute stroke. The cut-off value of cerebrospinal fluid NSE is 35 ng/ml. This value should only be considered as highly suggestive of CJD when other diseases, such as ischaemic stroke or brain tumours have been excluded. NSE in cerebrospinal fluid appears to be a valuable biochemical marker in cases of advanced dementia when the clinical diagnosis of CJD cannot be corroborated by electro-encephalography.²⁴

**Therapeutics for prion diseases**

The most attractive therapeutic target is interfering with the conversion of PrP⁰ into PrP⁰. There are several therapeutic strategies that can be suggested, i.e. stabilizing the structure of PrP⁰ by binding it to a drug; modifying the action of protein X, which might function as a molecular chaperone. The PrP⁰ formation seems to be limited to caveola-like domains so the drugs do not need to penetrate the cytols of the cells, but they must be able to enter the CNS. Drugs that destabilize the structure of PrP⁰ might also prove useful.⁷

The transformation of PrP⁰ into PrP⁰ requires an interaction of PrP⁰-PrP⁰. There are some sulfated polyanion compounds, such as pentosan sulfate, dextran sulfate, heparin, amyloid binding dye Congo red, that can irreversibly inhibit PrP⁰ formation and prion synthesis.¹¹,²² Coughey et al., cited by Beissen,¹¹ observed that PrP⁰ can bind directly to sulfated glycans, Congo red, and endogenous glycosaminoglycans, suggesting that sulfated polyanions may competitively inhibit PrP⁰-PrP⁰ interaction. Shyng et al.²⁵ found that these compounds could decrease the amount of PrP⁰ on the surface of neuroblastoma cells, by enhancing the rate of PrP⁰ endocytosis. The sulfated glycans may also redistribute a portion of PrP molecules to an endocytic compartment that is unfavorable for the conversion process.²⁵

Understanding how PrP⁰ unfolds and refolds into PrP⁰ may open new approach to deciphering the causes of and developing effective therapies for the more common neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.⁷

**CONCLUSION**

Prion is an infectious protein that cause neurodegenerative diseases in humans and animals. The prion protein (PrP) consists of two isoforms i.e. PrP⁰, the normal isoform, and PrP⁰ the abnormal one. The conversion of PrP⁰ into PrP⁰ is a posttranslational process that involves a conformational modification. How PrP⁰ can be converted into PrP⁰ remains to be established although several investigators have suggested some prion multiplication models. Understanding the prion propagation needs much more attention because it may contribute to the development of an effective therapy for these neurodegenerative diseases.

The development of premortem diagnostic test of prions is needed, since a definitive diagnosis of prion diseases by histopathological examination of a brain biopsy specimen is accompanied by high risks. There are biochemical markers, such as neuron-specific enolase and 14-3-3 protein in cerebrospinal fluid, which can provide an objective evidence for the diagnosis of prion diseases, especially the Creutzfeldt-Jakob disease. These markers can be detected by an immunochromatographic examination. However, these diagnostic tests should only be considered as a marker in appropriate clinical findings or when other diseases have been excluded.

The understanding of prion diseases might open a new and emerging area of investigation in molecular biology, cell biology, genetics, and protein chemistry.

**REFERENCES**

1. Prusiner SB. Genetic and infectious prion disease. Arch Neurol 1993;50:1129-53.
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:134-46.
3. Baldwin MA, Cohen FE, Prusiner SB. Prion protein isoforms, a convergence of biological and structural investigation. J Biol Chem 1995;270:19197-200.
4. Prusiner SB. Prions and neurodegenerative disease. N Engl J Med 1987;317:1571-81.
5. Estibiero JP. Multiple roles for PrP in the prion diseases. Trends Neurosci 1996;19:257-8.
6. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996;383:685-90.
7. Prusiner SB. Prion diseases and the BSE crisis. Science 1997;278:245-51.
8. Cohen FE, Pan KM, Huang Z, Baldwin M, Flitterick RJ, Prusiner SB. Structural clues to prion replication. Science 1994;264:530-1.
9. Collee JG, Bradley R. BSE: a decade on-part I. Lancet 1997;349:636-41.
10. Prusiner SB. Molecular biology and pathogenesis of prion diseases. Trends Biochem Sci 1996;21:482-7.
11. Bessen RA. Neurodegenerative prion disease. Science & Medicine 1996; 3:12-21.
12. Mayer RJ, Landon M, Laszlo L, Lennox G, Lowe J. Protein processing in lysosomes: the new therapeutic target in neurodegenerative disease. Lancet 1992;340:156-9.
13. Huang Z, Gabriel JM, Baldwin MA, Fletterick RJ, Prusiner SB, Cohen FE. Proposed three-dimensional structure for the cellular prion protein. Proc Natl Acad Sci USA 1994; 91:7139-43.
14. Martins VR, Graner E, Garcia-Abreu J, de Souza SJ, Mercadante AF, Viega SS, et al. Complementary hydropathy identifies a cellular prion protein receptor. Nature Med 1997;3:1376-82.
15. Rieger R, Edenhofer F, Lasmezas CI, Weiss. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nature Med 1997;3:1383-8.
16. Berg LJ. Insight into the role of the immune system in the prion diseases. Proc Natl Acad Sci USA 1994;91:429-32.
17. Vogel G. B cells may propagate prions. Science 1997;278:2050.
18. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, et al. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998; 279:827-34.
19. Epstein FH. Transmissible spongiform encephalopathies. N Engl J Med 1997;337:1821-8.
20. Aguzzi A. Neuro-immune connection in spread of prions in the body? Lancet 1997;349:742-3.
21. Collee JG, Bradley R. BSE: a decade on-part 2. Lancet 1997;349:715-21.
22. Sarkozi E, Askansas V, Engel WK. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol 1994;145:1280-4.
23. Hsich G, Kenney K, Gibbs CJ, Lee KH, Harrington MG. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 1996;335:924-30.
24. Zerr I, Bodemer M, Racker S, Grosche S, Poser S, Kretzschmar HA, et al. Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 1995;345:1609-10.
25. Shyng S-L, Lehmann S, Moulder KL, Harris DA. Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrP\textsuperscript{C}, in cultured cells. J Biol Chem 1995; 270:30221-9.